previou
review
antivir
agent
annual
report
medicin
chemistri
emphas
compound
activ
dna
virus
primarili
rna
virus
antidna
viru
agent
provid
antivir
agent
activ
rna
virus
previous
review
neither
interferon
interferon
induc
includ
review
cover
volum
respect
sever
review
publish
give
overview
promis
clinic
experiment
antivir
provid
background
viral
diseas
specif
drug
cite
section
compound
discuss
focu
year
chapter
agent
activ
brief
updat
year
advanc
comprehens
review
deal
viral
respiratori
diseas
rna
virus
major
caus
factor
variou
form
acut
respiratori
diseas
respiratori
tract
probabl
common
caus
symptomat
human
infect
among
children
adult
acut
respiratori
tract
ill
result
signific
morbid
lost
time
work
physician
visit
death
calcul
throughout
world
two
million
death
occur
annual
acut
respiratori
diseas
compris
five
taxonom
distinct
famili
orthomyxovirida
paramyxovirida
picornavirida
coronavirida
adenovirida
influenza
virus
compris
type
b
c
belong
famili
orthomyxovirida
type
b
associ
signific
increas
mortal
epidem
diseas
may
asymptomat
caus
symptom
rang
common
cold
fatal
pneumonia
immun
influenza
recommend
highrisk
group
antivir
chemotherapi
amantadin
avail
treatment
prophylaxi
influenza
infect
famili
paramyxovirida
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
major
caus
lower
respiratori
tract
infect
rsv
factor
sever
bronchiol
pneumonia
infant
young
children
effort
develop
vaccin
rsv
ineffectu
recent
clinic
trial
ribavirin
small
particl
aerosol
promis
parainfluenza
virus
four
human
serotyp
second
rsv
caus
lower
respiratori
tract
ill
great
need
interest
develop
chemotherapeut
agent
treatment
two
viral
respiratori
tract
pathogen
famili
picornavirida
contain
genu
rhinoviru
compos
hundr
distinct
serotyp
virus
recogn
import
caus
agent
upper
respiratori
tract
ill
although
technic
difficulti
appear
hinder
studi
vaccin
antivir
agent
adenovirus
famili
adenovirida
ubiquit
group
doublestrand
dna
virus
respons
wide
varieti
respiratori
ill
infect
common
among
children
although
acut
respiratori
diseas
pneumonia
also
common
among
militari
recruit
two
comprehens
review
viral
respiratori
diseas
measur
control
treatment
recent
publish
p
develop
vaccin
preclud
due
coronavirus
famili
coronavirida
also
appreci
role
agent
activ
primarili
rna
virus
amantadin
ladamantanamin
rimantadin
amethvlladamantanemethvlaminel
amantadin
rimantadin
specif
activ
influenza
viru
infect
amantadin
licens
gener
use
largescal
trial
drug
highli
effect
signific
differ
rate
ill
infect
two
drugtreat
group
amantadin
recipi
report
higher
incid
side
effect
larg
attribut
central
nervou
system
cn
symptom
effect
may
pharmacokinet
phen
menon
result
higher
plasma
concentr
amantadin
lg
control
studi
healthi
adult
volunt
found
minor
side
effect
compar
common
antihistamin
hospit
employe
receiv
amantadin
show
high
incid
cn
symptom
guidelin
use
amantadin
patient
impair
renal
function
formul
result
pharmacokinet
studi
amantadin
patient
normal
impair
renal
sinc
approxim
oral
dose
amantadin
excret
unchang
urin
patient
renal
insuffici
accumul
drug
result
toxic
manifest
mechan
inhibit
influenza
viru
replic
previous
narrow
virusspecif
event
viru
penetr
prior
primari
transcript
radioact
precursor
seem
show
uncoat
multistep
rimantadin
prevent
second
step
uncoatin
releas
matrix
protein
ribonucleoprotein
rnp
block
penetr
rnp
nucleu
prevent
nuclear
phase
viru
reproduct
amantadin
produc
effect
uncoat
adamantyl
amin
may
also
util
treatment
type
viral
infect
shown
effect
inhibitor
dengu
viru
replic
amelior
postherpet
neuralgia
due
recurr
herp
simplex
acut
herp
report
earli
administr
amantadin
ribavirin
nucleosid
activ
broad
rang
dna
rna
virus
tissu
cultur
anim
model
analysi
statu
ribavirin
still
unresolv
may
involv
guanosin
nucleotid
inhibit
inosin
monophosph
clinic
trial
influenza
oral
ribavirin
fail
alter
clinic
sign
symptom
howev
recent
report
therapeut
effect
influenza
influenza
b
viru
infect
administ
patient
inhal
smallparticl
aerosol
face
k
find
util
patient
high
risk
elderli
chronic
ill
ribavirin
also
shown
inhibit
respiratori
syncyti
viru
rsv
infect
anim
model
administ
ip
aerosol
treatnentg
vivo
activ
substanti
two
control
doubleblind
clinic
r
l
administr
continu
aerosol
ribavirin
infant
hospit
lower
respiratori
tract
diseas
rsv
result
signific
clinic
sever
antivir
agent
colorado
tick
fever
viru
ctfv
ribavirin
inhibit
ctfv
ribavirin
protect
mice
inocul
intracerebr
ctfv
howev
deriv
significantli
increas
number
survivor
administ
ip
suggest
lipophil
prodrug
ribavirin
abl
crass
bloodbrain
barrier
administr
also
found
protect
mice
inocul
intracerebr
dengu
viru
condit
ribavirin
signific
protect
anoth
studi
ribavirin
reduc
growth
four
type
dengu
viru
vitro
effect
viru
replic
human
peripher
blood
leukocyt
pbl
implic
pathogenesi
dengu
viru
howev
combin
ribavirin
purin
inhibitor
hypoxanthineguanin
phosphoribosyl
transferas
result
mark
suppress
dengu
viru
replic
human
signific
progress
continu
made
clinic
use
develop
agent
activ
dna
virus
guanin
subject
sever
r
e
v
past
year
clinic
trial
result
publish
attest
efficaci
oral
acyclovir
treatment
genit
herp
simplex
viru
hsv
infect
protect
bone
marrow
transplant
patient
herp
highli
effect
suppress
recurr
herp
sim
lex
genitali
group
patient
unusu
frequent
topic
acyclovir
cream
effect
treatment
recurr
herp
consider
progress
made
evalu
clinic
promis
acyclovir
howev
remain
much
learn
concern
best
use
drug
clinic
studi
candid
prodrug
form
acyclovir
recent
publish
sever
ester
acyclovir
report
improv
acyclovir
chronic
oral
acyclovir
treatment
water
hydroxyethoxymethyl
purin
metabol
deamin
acyclovir
adenosin
report
better
absorb
gut
result
higher
plasma
level
sever
new
report
document
potent
antiherpet
activ
hydroxymethyl
ethoxymethyl
guanin
compound
report
highli
effect
reduc
sever
primari
recurr
lesion
anim
also
appear
hold
substanti
promis
treatment
human
cytom
aloviru
hcmv
base
specif
antihcmv
activ
v
ro
anim
model
hydroxym
guanin
shown
potent
oral
activ
chemotherapeut
agent
equid
herpesviru
report
stabil
cutan
lesion
immunosuppress
patient
suffer
acut
herpesviru
minor
metabolit
fiac
fmau
also
antiherpet
addit
ip
activ
murin
leukemia
resist
pharmacokinet
studi
fiac
fmau
pblish
synthesi
itro
antihsv
antivir
activ
bvdu
e
pyrimidin
nucleosid
analog
publish
sever
prodrug
form
araa
lbqarabinofuranosyl
adenin
evalu
favor
result
induc
genit
infect
femal
guinea
pig
araa
found
effect
araa
treatment
immunosuppress
patient
suffer
varicellazost
carbocycl
analog
araa
cyclaradin
ester
report
activ
enceph
anim
model
compar
activ
demonstr
araago
two
compound
may
possess
clinic
advantag
araa
due
low
system
toxic
acid
pfa
foscarnet
sodium
present
phase
clinic
trial
discuss
recent
synthesi
structur
requir
antiherp
activ
seri
pfa
ester
also
diaminopurin
analog
seri
analog
report
k
review
antivir
effect
phosphonoform
approach
design
antivir
agent
signific
stride
made
develop
clinic
use
antivir
agent
especi
dna
virus
herp
famili
agent
direct
viral
nucleic
acid
synthesi
requir
activ
virusinduc
thymidin
kinas
research
begin
focu
strategi
may
produc
broader
spectrum
antivir
agent
differ
mechan
action
inhibit
polyamin
biosynthesi
may
serv
suitabl
target
antivir
drug
design
bi
udifluoromethylornithin
inhibitor
polyamin
biosynthesi
recent
report
inhibit
replic
human
cmv
methyl
reaction
virus
effici
replic
depend
viral
mrna
methyl
guanosin
residu
effect
inhibitor
cappin
mrna
ganin
methyltransferas
anoth
permut
theme
preserv
cellular
sadenosylhomocystein
sah
inhibit
sah
hydrolas
sah
endogen
inhibitor
transmethyl
polyamin
antimetabolit
methylglyox
anoth
target
inhibit
essenti
ribavirin
report
reaction
catalyz
reaction
sadenosylmethionin
methyl
donor
system
substanti
interest
exploit
system
approach
antivir
drug
develop
primarili
aim
synthesi
core
analog
permeabl
cell
stabl
degrad
enzym
process
infect
virus
chang
permeabl
infect
cell
allow
cellular
penetr
compound
normal
exclud
select
antivir
activ
hygromycin
b
support
suggest
screen
agent
select
permeabl
viru
infect
cell
could
result
broadspectrum
antivir
agent
review
concept
select
deliveri
antivir
agent
con
jugat
protein
carrier
publish
activ
appear
mediat
obligatori
lysosom
step
uncoat
envelop
virus
amin
chloroquin
may
prevent
uncoat
increas
lysosom
ph
valu
requir
releas
viru
nucleocapsid
cytoplasm
better
understand
process
could
lead
develop
broadspectrum
antivir
agent
one
mechan
interferon
exert
antivir
effort
